In short, the results discussed above clearly demonstrate that DNA damage can trigger SIPS in human cancer cell lines expressing wild-type or mutant p53, and that this response is associated with nuclear accumulation of p21 in the majority of cases, and with induction of p16 in some cases. The gene discussed is CDKN2A; the disease is cancer.